AbCellera Biologics (ABCL) Aandelenoverzicht
AbCellera Biologics Inc. houdt zich bezig met het ontdekken en ontwikkelen van geneesmiddelen op basis van antilichamen voor indicaties met een onbeantwoorde medische behoefte in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
ABCL Community Fair Values
Create NarrativeSee what 106 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbCellera Biologics Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$10.89 |
| 52 Week Hoogtepunt | US$12.58 |
| 52 Week Laag | US$2.75 |
| Bèta | 1.32 |
| 1 maand verandering | -0.73% |
| 3 maanden verandering | 107.82% |
| 1 Jaar Verandering | 143.62% |
| 3 jaar verandering | 103.93% |
| 5 jaar verandering | -46.51% |
| Verandering sinds IPO | -81.51% |
Recent nieuws en updates
Narratiefupdate • Sep 08
ABCL: Menopause Program Hype And Jazz Deal Will Eventually Face Reality
Analysts lifted their fair value estimate for AbCellera Biologics from $7.00 to $9.00 and referenced sharply higher price targets of $25 and $30 that are linked to stronger confidence in ABCL635 and recent partnership progress. Analyst Commentary on AbCellera Biologics Recent research coverage on AbCellera Biologics has focused on two areas.
Narratiefupdate • Aug 24
ABCL: Menopause Program Progress And Jazz Deal Will Drive Future Upside
AbCellera Biologics' fair value estimate has moved from $13.00 to $30.00, as analysts point to stronger perceived potential for ABCL635 in menopausal vasomotor symptoms following Phase 2 data and updated projections for a multibillion dollar market opportunity. Analyst Commentary Recent Street research on AbCellera Biologics has shifted firmly toward a more constructive view, with several bullish analysts revisiting their price frameworks following the latest Phase 2 data for ABCL635 in menopausal vasomotor symptoms and the new collaboration activity.Recent updates
Narratiefupdate • Sep 08
ABCL: Menopause Program Hype And Jazz Deal Will Eventually Face Reality
Analysts lifted their fair value estimate for AbCellera Biologics from $7.00 to $9.00 and referenced sharply higher price targets of $25 and $30 that are linked to stronger confidence in ABCL635 and recent partnership progress. Analyst Commentary on AbCellera Biologics Recent research coverage on AbCellera Biologics has focused on two areas.Narratiefupdate • Aug 24
ABCL: Menopause Program Progress And Jazz Deal Will Drive Future Upside
AbCellera Biologics' fair value estimate has moved from $13.00 to $30.00, as analysts point to stronger perceived potential for ABCL635 in menopausal vasomotor symptoms following Phase 2 data and updated projections for a multibillion dollar market opportunity. Analyst Commentary Recent Street research on AbCellera Biologics has shifted firmly toward a more constructive view, with several bullish analysts revisiting their price frameworks following the latest Phase 2 data for ABCL635 in menopausal vasomotor symptoms and the new collaboration activity.Seeking Alpha • Aug 11
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading
Summary AbCellera Biologics has shifted from a pure platform-for-hire to developing its own pipeline, notably ABCL635 for menopausal vasomotor symptoms. ABCL635, a monoclonal antibody targeting NK3R, offers monthly dosing versus daily oral competitors, with Phase 2 data showing strong efficacy at four weeks. Cross-trial comparisons suggest ABCL635's efficacy is promising, but small sample size and early-stage data limit the strength of 'best-in-class' claims. The safety profile is encouraging but not definitive; a transaminase elevation in one patient raises caution, echoing early signals seen in competitor drugs. Read the full article on Seeking Alpha
Narratiefupdate • Aug 10
ABCL: Menopause Antibody Data Will Drive Bullish Repricing In Coming Years
Analysts have lifted their fair value estimate for AbCellera Biologics from $10.43 to $14.63, citing higher Street price targets tied to positive ABCL635 Phase 2 data and expectations for future revenue from the new Jazz Pharmaceuticals development agreement. Analyst Commentary Street research on AbCellera Biologics has turned more constructive in recent months, with several firms adjusting ratings and price targets following clinical and partnership updates.Analyse-artikel • Aug 10
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%
Today is shaping up negative for AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders, with the analysts delivering a...Narratiefupdate • Jul 09
ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook
The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.Narratiefupdate • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Narratiefupdate • Jun 10
ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion
The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.Narratiefupdate • May 26
ABCL: GPCR Platform Progress And Upcoming Women’s Health Data Will Drive Upside
Analysts lifted their price target on AbCellera Biologics by $1, citing recent bullish initiations and research that view the company’s profile as increasingly attractive relative to selected peers. Analyst Commentary Recent Street research on AbCellera Biologics highlights a mix of optimism and caution, with several firms updating their views and price targets in light of the company’s current positioning and peer comparisons.Analyse-artikel • May 14
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
AbCellera Biologics Inc. ( NASDAQ:ABCL ) investors will be delighted, with the company turning in some strong numbers...Narratiefupdate • May 06
ABCL: Platform And Partnerships Will Support Future Upside From GPCR Pipeline Progress
The analyst price target for AbCellera Biologics has shifted to $7.00, with analysts pointing to updated assumptions around the discount rate, revenue growth, profit margins, and a very large future P/E multiple. This view is supported by recent bullish Street coverage that frames the company as increasingly attractive relative to certain peers.Narratiefupdate • Apr 20
ABCL: Platform And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target on AbCellera Biologics to $7.00. The change reflects updated assumptions around revenue trends, profit margins, discount rates, and future P/E, supported by recent research that takes a bullish view on the stock.Narratiefupdate • Apr 06
ABCL: Menopause Phase 2 Progress Will Support Future Upside Potential
Analysts maintained their $7.00 price target for AbCellera Biologics, citing only very small adjustments to assumptions around discount rate, revenue trends, profit margin, and future P/E as the basis for keeping their overall valuation view steady. What's in the News AbCellera Biologics has started dosing patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narratiefupdate • Mar 22
ABCL: Menopause Trial Progress Will Drive Future Share Price Upside
Analysts have trimmed their price targets on AbCellera Biologics to $7.00, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple that together point to a more cautious outlook on how quickly the business may scale. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narratiefupdate • Mar 08
ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook
Analysts have lowered their price target on AbCellera Biologics from $15.88 to $12.00, reflecting updated views on fair value, revenue growth expectations, and future P/E assumptions. What's in the News The first patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narratiefupdate • Feb 22
ABCL: Menopause Phase 2 Progress And Bruker Settlement Will Support Future Margins
Analysts have maintained their $9.83 price target on AbCellera Biologics, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which they view as collectively balanced at this stage. What's in the News AbCellera began dosing patients in the Phase 2 portion of its ongoing Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narratiefupdate • Feb 08
ABCL: Clinical Progress And Royalty Deal Will Drive Future Share Price Upside
Analysts have reduced their price target on AbCellera Biologics, citing updated assumptions that incorporate higher expected revenue growth and profit margins, partially offset by a lower projected future P/E multiple. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narratiefupdate • Jan 24
ABCL: Phase 2 Menopause Trial Progress Will Support Future Profit Margins
Analysts have trimmed their price target on AbCellera Biologics to US$9.83, reflecting slightly lower discount rate assumptions, a modestly higher long term profit margin outlook, and a small adjustment to future P/E expectations. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narratiefupdate • Jan 08
ABCL: Patent Settlement Cash Flows Will Support A Stronger Future Outlook
Analysts have trimmed their implied fair value estimate for AbCellera Biologics from about US$17.00 to roughly US$15.88, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News AbCellera reached a global settlement and patent license agreement with Bruker Corporation, resolving ongoing patent litigation between the two companies (Key Developments).Narratiefupdate • Dec 14
ABCL: Higher Future Earnings Multiple Will Drive Strong Share Price Upside
Analysts have raised their price target on AbCellera Biologics by approximately 40 percent to reflect a higher fair value estimate of around 7 dollars per share. They cite expectations for modestly slower revenue growth, offset by improved profit margins and a richer future earnings multiple.Narratiefupdate • Nov 29
ABCL: Upcoming Clinical Trial Results Will Drive Future Profit Margins Higher
Analysts have adjusted their price target for AbCellera Biologics slightly downward from $10.20 to $9.83 per share. This change reflects more conservative expectations around future revenue growth and profit margins.Narratiefupdate • Nov 15
ABCL: Upcoming Clinical Trial Results Are Expected To Drive Profit Margins Higher
Analysts have raised their price target for AbCellera Biologics from $9.33 to $10.20 per share, citing improved profit margin forecasts even though revenue growth expectations have slightly moderated. What's in the News AbCellera Biologics has begun dosing the first participants in a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate to severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions (Key Developments).Nieuw narratief • May 18
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.Analyse-artikel • May 15
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
The latest analyst coverage could presage a bad day for AbCellera Biologics Inc. ( NASDAQ:ABCL ), with the analysts...Seeking Alpha • Apr 17
AbCellera: Attractively Priced But A Catalyst Is Needed
Summary AbCellera's stock remains under pressure due to a shift towards internal development, which has reduced revenue and increased cash burn. AbCellera retains a large cash position, though, giving it a multi-year runway in which to demonstrate the merits of its platform. AbCellera's low enterprise value suggests that investors are either skeptical of the company's platform or ignoring its cash position. A more favorable macro environment and clinical success will likely be needed before AbCellera's stock moves meaningfully higher. Read the full article on Seeking AlphaSeeking Alpha • Mar 15
AbCellera: Burning Cash, Searching For 'Blockbusters'
Summary AbCellera's revenues plummeted post-COVID antiviral sales, leading to a significant net loss and an 85% drop in share price, now at ~$2.5. The company is pivoting to develop its own drug pipeline, with ABCL635 and ABCL575 in late-preclinical stages, targeting metabolic and inflammatory conditions. Financially, AbCellera has ~$840 million in liquidity, but its market cap is lower than its cash reserves, reflecting skepticism about its assets. The company's future hinges on successfully developing a blockbuster drug, with key catalysts not expected until 2026, making its current valuation a gamble. Read the full article on Seeking AlphaSeeking Alpha • Dec 23
AbCellera Biologics: Still A Concept Stock
Summary Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
It's shaping up to be a tough period for AbCellera Biologics Inc. ( NASDAQ:ABCL ), which a week ago released some...Seeking Alpha • Oct 14
AbCellera: A Platform To Pipeline Transition
Summary AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
AbCellera: A Waiting Game With High Uncertainty
Summary AbCellera’s Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company’s net loss widened to $36.9 million due to increased R&D expenses. AbCellera’s cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million. The number of molecules in clinical trials increased from nine to 14 within a year. A "hold" recommendation is maintained due to the speculative and high-risk nature of AbCellera’s business. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ABCL | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | -4.7% | -1.9% | -1.0% |
| 1Y | 143.6% | 25.1% | 14.1% |
Rendement versus industrie: ABCL overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 25.1 % opleverde.
Rendement versus markt: ABCL overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.1 %.
Prijsvolatiliteit
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 15.5% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: De aandelenkoers van ABCL is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 16% ) van ABCL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2012 | 562 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. houdt zich bezig met het ontdekken en ontwikkelen van op antilichamen gebaseerde geneesmiddelen voor aandoeningen waarvoor in de Verenigde Staten nog geen adequate behandeling bestaat. Het belangrijkste product van het bedrijf is ABCL635, een niet-hormonaal geneesmiddel dat zich momenteel in een fase 2-klinische studie bevindt voor de behandeling van matige tot ernstige vasomotorische symptomen; en ABCL575, een volledig humaan monoklonaal antilichaam met verlengde halfwaardetijd, dat zich in een fase 1-klinische studie bevindt voor de behandeling van door T-cellen gemedieerde auto-immuunziekten, zoals atopische dermatitis. Het bedrijf heeft een samenwerkings- en licentieovereenkomst op het gebied van onderzoek met Eli Lilly and Company; AbbVie Inc.; en Jazz Pharmaceuticals plc voor de ontwikkeling van multispecifieke antilichamen die T-cellen activeren (TCE’s); een samenwerkingsovereenkomst met Viking Global Investors & ArrowMark Partners en Biogen Inc.; en Vertex Pharmaceuticals Incorporated voor het onderzoek naar, de ontwikkeling, productie en commercialisering van multispecifieke T-cel-bindende antilichamen (TCE’s) voor auto-immuunziekten en andere aandoeningen.
AbCellera Biologics Inc. Samenvatting
| ABCL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$3.53b |
| Inkomsten(TTM) | -US$164.66m |
| Inkomsten(TTM) | US$66.17m |
53.3x
P/S-verhouding-21.4x
Koers/WinstverhoudingIs ABCL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ABCL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$66.17m |
| Kosten van inkomsten | US$197.77m |
| Brutowinst | -US$131.60m |
| Overige uitgaven | US$33.06m |
| Inkomsten | -US$164.66m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.51 |
| Brutomarge | -198.88% |
| Nettowinstmarge | -248.84% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ABCL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/12 14:41 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
AbCellera Biologics Inc. wordt gevolgd door 13 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Guyn Kim | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Steven Seedhouse | Cantor Fitzgerald & Co. |